# US 2023/0272019 A1 · Fungal glycan binding protein which possesses antiviral and anticancer activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272019 A1
- Document ID: US20230272019A1
- Status: Published application
- Kind: A1
- Application number: 18/050,485
- Filed: 2022-10-28
- Published: 2023-08-31
- Earliest claimed: 2017-07-26
- Assignees: University of Florida Research Foundation, Inc.
- Applicants: University of Florida Research Foundation, Incorporated
- Inventors: Yousong Ding; Peilan Zhang; Steven Douglas Bruner
- Web page: https://patentgrep.com/patent/US20230272019A1

## CPC

- C07K 14/37: from fungi
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The subject invention pertains to compositions and methods for preparing and using recombinant proteins based on the fungal Coprinus comatus Y3 protein to control plant and animal viruses and microbes, and diagnose, prevent and treat cancers. Methods are disclosed using compositions comprising recombinant Y3 proteins to diagnose, prevent and/or treat cancer diseases based on recombinant Y3 protein interaction with glycans expressed on cancer cells.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A method of killing cancer cells in a subject, the method comprising: administering to a subject suspected of having cancer cells a composition comprising a recombinant Y3 protein, wherein the recombinant Y3 protein comprises the sequence set forth in SEQ ID NO: 3 and lacks amino acid residues 1-18 of SEQ ID NO: 1.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the subject is suspected of having breast cancer, ovarian cancer, uterine cancer, or a blood cancer.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the blood cancer is a leukemia.

### Claim 32 (depends on 29)

The method of claim 29, wherein the subject is a human.

### Claim 33 (depends on 29)

The method of claim 29, wherein the recombinant Y3 protein is conjugated to one or more marker molecules.

### Claim 34 (depends on 29)

The method of claim 29, wherein the recombinant Y3 protein is conjugated to one or more therapeutic molecules.

### Claim 35 (depends on 33)

The method of claim 33, wherein the marker molecule is a molecule that emits a radioactive or a fluorescent signal.

### Claim 36 (depends on 34)

The method of claim 34, wherein the therapeutic molecule is a radioactive molecule, a cytotoxic molecule, an apoptosis-inducing molecule, an antisense oligonucleotide, doxorubicin, 5-fluorouracil, methotrexate, pyrrolobenzodiazepine, calicheamicin, maytanisinoid, ausristatin, pyrrolobenzodiazepine, mertansine/emtansine, ravtansine/soravtansine, vincristine, vinblastine, etoposide, melphalan, mitomycin C, chlorambucil, daunorubicin, ricin, a thalidomide or a thalidomide analog, dolastatin, trichothecene, enediyne, taxane, anthracycline, adriamycin, vindesine, vinca alkaloid, teniposide, carminomycin, aminopterin, dactinomycin, bleomycin, esperamicin, tubulysin, cryptophycin, erlotinib, bortezomib, fulvestrant, sunitinib, letrozole, imatinib mesylate, oxaliplatin, leucovorin, rapamycin, lapatinib, lonafarnib, sorafenib, gefitinib, capecitabine, duocarmycin, lexitropsin, nitrosourea, platinol, purine antimetabolite, puromycin, steroid, purine antagonist, androgen, 5-azacytidine, azathioprine, busulfan, buthionine sulfoximine, camptothecin, carboplatin, carmustine, estrogen, 5-fluordeoxyuridine, gramicidin D, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, mithramycin, mitoxantrone, nitroimidazole, plicamycin, procarbizine, streptozotocin, tenoposide, 6-thioguanine, topotecan, vinorelbine, acyclovir, gangcyclovir, zidovudine, vidarabine, ribavarin, azidothymidine, cytidine arabinoside, amantadine, dideoxyuridine, iododeoxyuridine, poscarnet, or trifluridine.

### Claim 37

A method of killing cancer cells in a subject, the method comprising: administering to a subject suspected of having cancer cells a composition comprising a recombinant Coprinus comatus Y3 protein consisting of amino acid residues 24 to 126 of SEQ ID NO: 1.

### Claim 38 (depends on 37)

The method of claim 37, wherein the subject is suspected of having breast cancer, ovarian cancer, uterine cancer, or a blood cancer.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the blood cancer is a leukemia.

### Claim 40 (depends on 37)

The method of claim 37, wherein the subject is a human.

### Claim 41 (depends on 37)

The method of claim 37, wherein the recombinant Coprinus comatus Y3 protein is conjugated to one or more marker molecules.

### Claim 42 (depends on 37)

The method of claim 37, wherein the recombinant Coprinus comatus Y3 protein is conjugated to one or more therapeutic molecules.

### Claim 43 (depends on 41)

The method of claim 41, wherein the marker molecule is a molecule that emits a radioactive or a fluorescent signal.

### Claim 44 (depends on 42)

The method of claim 42, wherein the therapeutic molecule is a radioactive molecule, a cytotoxic molecule, an apoptosis-inducing molecule, an antisense oligonucleotide, doxorubicin, 5-fluorouracil, methotrexate, pyrrolobenzodiazepine, calicheamicin, maytanisinoid, ausristatin, pyrrolobenzodiazepine, mertansine/emtansine, ravtansine/soravtansine, vincristine, vinblastine, etoposide, melphalan, mitomycin C, chlorambucil, daunorubicin, ricin, a thalidomide or a thalidomide analog, dolastatin, trichothecene, enediyne, taxane, anthracycline, adriamycin, vindesine, vinca alkaloid, teniposide, carminomycin, aminopterin, dactinomycin, bleomycin, esperamicin, tubulysin, cryptophycin, erlotinib, bortezomib, fulvestrant, sunitinib, letrozole, imatinib mesylate, oxaliplatin, leucovorin, rapamycin, lapatinib, lonafarnib, sorafenib, gefitinib, capecitabine, duocarmycin, lexitropsin, nitrosourea, platinol, purine antimetabolite, puromycin, steroid, purine antagonist, androgen, 5-azacytidine, azathioprine, busulfan, buthionine sulfoximine, camptothecin, carboplatin, carmustine, estrogen, 5-fluordeoxyuridine, gramicidin D, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, mithramycin, mitoxantrone, nitroimidazole, plicamycin, procarbizine, streptozotocin, tenoposide, 6-thioguanine, topotecan, vinorelbine, acyclovir, gangcyclovir, zidovudine, vidarabine, ribavarin, azidothymidine, cytidine arabinoside, amantadine, dideoxyuridine, iododeoxyuridine, poscarnet, or trifluridine.

### Claim 45 (depends on 29)

A method of treating a disease caused by microbes or viruses in a subject, the method comprising: administering to a subject suspected of having a disease caused by microbes or viruses a composition according to claim 29.

### Claim 46 (depends on 37)

A method of treating a disease caused by microbes or viruses in a subject, the method comprising: administering to a subject suspected of having a disease caused by microbes or viruses a composition according to claim 37.
